Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor

Related articles

1. Discovery of Potent Kinase Inhibitors with Improved Pharmacokinetics and Safety Through Structural Optimization of Dasatinib

   This article has 1 author:

   1. Kan He

2. Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models

   This article has 12 authors:

   1. Daniela De Nobrega
   2. Logan C. Eiler
   3. Parmanand Ahirwar
   4. Urvi P. Rawal
   5. Chelsea L. Crawford
   6. Donald J. Buchsbaum
   7. Adam B. Keeton
   8. Yulia Y. Maxuitenko
   9. Xi Chen
   10. Gary A. Piazza
   11. Allan Tsung
   12. Karim I. Budhwani

3. A Multitargeted Approach to Breast Cancer Therapy: Exploring the Therapeutic Potential of Afzelin as a Combination Agent with FDA-Approved Breast Cancer Drugs.

   This article has 3 authors:

   1. Dhilna francis
   2. ABI T.G
   3. BINITHA R.N